Smarter Decisions,
Better Care
UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point of care decisions.
For more information, click below.
Subscribers log in here
Related articles
| AuthorsLesley A Inker, MD, MSRonald D Perrone, MD | Section EditorRichard H Sterns, MD | Deputy EditorJohn P Forman, MD, MSc |
Topic Outline
INTRODUCTION
An elevation in the serum creatinine concentration (SCr) usually reflects a reduction in the glomerular filtration rate and is associated with a concomitant rise in the blood urea nitrogen (BUN). (See "Assessment of kidney function".)
There are, however, a variety of settings in which the SCr can increase acutely independent of the GFR, and therefore, in which there is no true change in overall kidney function. This may be due to one of three factors: decreased creatinine secretion; interference with the serum assay; or enhanced creatinine production.
DECREASED SECRETION
In normal subjects, approximately 15 percent of the urinary creatinine is derived from secretion in the proximal tubule. This value can rise to as high as 50 percent in patients with advanced kidney disease and accounts for the overestimation of the true GFR by the creatinine clearance [1]. (See "Calculation of the creatinine clearance".)
Creatinine is an organic cation in the physiologic pH range and is secreted by the organic cation secretory pump that can be inhibited by other organic cations. Commonly used drugs that can interfere with creatinine secretion and, therefore, result in a self-limited and reversible rise in the SCr by as much as 0.4 to 0.5 mg/dL (35 to 44 micromol/L) without changing the true GFR include:
Subscribers log in here